$-0.38 EPS Expected for Verastem, Inc. (VSTM)

March 14, 2018 - By Stephen Andrade

 $ 0.38 EPS Expected for Verastem, Inc. (VSTM)
Investors sentiment increased to 1.4 in Q3 2017. Its up 0.23, from 1.17 in 2017Q2. It is positive, as 6 investors sold Verastem, Inc. shares while 19 reduced holdings. 19 funds opened positions while 16 raised stakes. 12.96 million shares or 49.25% more from 8.68 million shares in 2017Q2 were reported.
Barclays Pcl invested in 0% or 900 shares. Artal Grp Sa holds 0.06% or 750,000 shares in its portfolio. Axa holds 59,307 shares. Tower Research (Trc) owns 579 shares or 0% of their US portfolio. Moreover, Raymond James & Associates has 0% invested in Verastem, Inc. (NASDAQ:VSTM) for 58,406 shares. Thompson Davis Com owns 1,200 shares. Deutsche Bancshares Ag accumulated 224,591 shares. Susquehanna Gru Limited Liability Partnership reported 75,526 shares or 0% of all its holdings. Invesco Ltd invested in 72,656 shares or 0% of the stock. Blackrock Incorporated has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Savings Bank Of Mellon owns 30,786 shares for 0% of their portfolio. Millennium Mgmt Limited Co holds 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 185,449 shares. Dimensional Fund L P reported 561,969 shares. Ellington Mngmt Grp Ltd Liability Corporation stated it has 0.02% of its portfolio in Verastem, Inc. (NASDAQ:VSTM). 1.19M were reported by Deer Vii & Limited.

Analysts expect Verastem, Inc. (NASDAQ:VSTM) to report $-0.38 EPS on March, 22.They anticipate $0.06 EPS change or 18.75 % from last quarter’s $-0.32 EPS. After having $-0.61 EPS previously, Verastem, Inc.’s analysts see -37.70 % EPS growth. The stock increased 0.60% or $0.02 during the last trading session, reaching $3.38. About 564,619 shares traded. Verastem, Inc. (NASDAQ:VSTM) has risen 71.53% since March 14, 2017 and is uptrending. It has outperformed by 54.83% the S&P500.

Verastem, Inc. (NASDAQ:VSTM) Ratings Coverage

Among 11 analysts covering Verastem (NASDAQ:VSTM), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Verastem had 30 analyst reports since September 9, 2015 according to SRatingsIntel. Raymond James downgraded the shares of VSTM in report on Tuesday, September 29 to “Outperform” rating. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 16. The firm has “Neutral” rating given on Monday, September 28 by Mizuho. On Thursday, June 8 the stock rating was maintained by Cantor Fitzgerald with “Hold”. The firm has “Hold” rating given on Tuesday, September 29 by Cantor Fitzgerald. On Thursday, March 8 the stock rating was initiated by FBR Capital with “Buy”. As per Tuesday, July 25, the company rating was maintained by Oppenheimer. On Tuesday, August 8 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) rating on Sunday, June 4. Oppenheimer has “Buy” rating and $600 target. TH Capital downgraded the stock to “Neutral” rating in Monday, September 28 report.

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $170.82 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

More recent Verastem, Inc. (NASDAQ:VSTM) news were published by: Businesswire.com which released: “Verastem Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)” on March 02, 2018. Also Businesswire.com published the news titled: “Verastem to Present at Upcoming Conferences” on March 13, 2018. Businesswire.com‘s news article titled: “Verastem Reports Year-End 2017 Financial Results” with publication date: March 13, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: